Natera
Court Grants Natera Injunction Against Invitae, ArcherDx in Use of Patented Products
The defendants are barred from using Personalized Cancer Monitoring products except for ongoing clinical trials, studies undergoing peer review, and quality control.
360Dx Top 30 Rebounds From Months of Decline, Rising 9 Percent in November
Of the 30 companies in the index, 24 firms saw their stock prices increase, while six saw their share prices decline.
As Clinical MRD Tests Boom, Natera Expands Efforts to Build Evidence for New Cancer Indications
Premium
Significant volume growth for its Signatera minimal residual disease test helped boost the company's Q3 revenues.
Foundation Medicine, Natera Launch ctDNA Therapy Response Assay With Medicare Coverage
The tissue-informed ctDNA assay is available to US physicians and is eligible for coverage through both the MolDx and New York's CLEP programs.
US Supreme Court Declines to Hear CareDx Organ Transplant Patent Infringement Case
CareDx had petitioned the US Supreme Court to hear a patent infringement case brought against Natera and Eurofins Viracor.
Sep 1, 2023
360Dx Top 30 Ticks Down in August
Jul 31, 2023